Payer agreements

265 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
265
On SlideShare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

Payer agreements

  1. 1. Payer Agreements: Splitting the Riskhttp://www.aarkstore.com/reports/Payer-Agreements-Splitting-the-Risk-170846.htmlBudgets are tight. Payer funding for new products isdwindling. And for pharmaceutical companies, marketaccess is more and more difficult to attain. Across the UK,the US, Canada, Australia and parts of Europe, payerschemes are increasingly de rigueur. Schemes advancedby pharmaceutical companies either aim to grapplefinancial issues such as price volume agreements, or theytackle uncertainty by addressing increased data collection.Report Overview In Payer Agreements: Splitting the Risk,FirstWord Dossier offers a complete and conciseoverview of payer schemes by definition and category.Based on an array of expert interviews, the reportdiscusses the key drivers behind the evolution of payerschemes from financial imperatives to market uncertainty.Most importantly, the report defines—country bycountry—emerging trends based on current case studiesand tackles the big question: What are the key featuresthat will ensure success? Key features Detailedexamination of the role of agreements in global pricing,reimbursement and market access Discussion of thedrivers for schemes, including HTA and financialchallenges Country-by-country trends illustrated with casestudies Expert insight into the role of schemes and theirevolution Analysis of the pros and cons of agreementsKey Benefits Definitions and categories of schemesExpert insight from key regulatory bodies Comprehensivereferences to key literature Key Questions Asked Whatprinciples should be used in designing schemes? Whenshould companies offer risk-sharing agreements? Howcan European risk-sharing be implemented in the US?What is the current state of play with schemes globallyWhat changes are likely in the future? Who Should ReadThis Report Market access directors and managers Healtheconomics professionals Health economics professionalsHealth Outcomes / Outcomes Research professionalsPricing and Reimbursement teams Government andregulatory affairs analysts Marketing research/businessintelligence managers Government and regulatory affairsanalysts Key quotes ―The current internationalpharmaceutical pricing framework is far too rigid.Manufacturers willing to openly differentiate the price fora given product in line with the different ability of various
  2. 2. payers to afford a product will be punished by theconsequences of international price referencing. At thesame time, price systems are barely capable ofdifferentiating the price for a single product that is used inmultiple indications according to its different valuepropositions.‖ – Ansgar Hebborn, Global Head, Payer andHTA Programme Policy, Roche ―Imagine in a time wherethose schemes could be really connected to one server.Like right at the patients bed people would enter the dataand so you would constantly be able to adjust and seeperformance and see small performance even in changesof dosing or changes or things. I know its very difficultbut I think eventually we might get there.‖ – UlfStaginnus, Head of Pricing & Health Economics Europe,Novartis and author of www.healtheconomicsblog.com―There is a lot of difference in the governance acrossEurope, which ultimately leads to quality of HTA. Animportant aspect is of course the independence of theassessment from the appraisal and ultimately the decisionon a certain price. Thats very, very different country bycountry and region by region.‖ – Ansgar Hebborn, GlobalHead, Payer and HTA Programme Policy, Roche ExpertViews Alicia Granados: MD. Senior Director Global HTAStrategy, GMA Genzyme Andrea Rappagliosi: VicePresident European Government Affairs & Head ofBrussels Office, GlaxoSmithKline Andrew Hobbs:Managing Director, Pope Woodhead and AssociatesLimited Ansgar Hebborn: Global Head, Payer and HTAProgramme Policy, Roche Clare McGrath: SeniorDirector HTA Policy, Pfizer David Grainger: GlobalPublic Policy Director, Lilly Günter Harms: MarketAccess & Public Affairs Director, Shire Human GeneticTherapies Kalipso Chalkidou: Director of InternationalDivision, National Institute for Health and ClinicalExcellence Karen Facey: Evidence based health policyconsultant and non-executive Director at NHS ForthValley, and Chair of the HTAi Interest Group forPatient/Citizen Involvement in HTA Larry Gorkin:President, Gorkin and Cheddar Consulting Mel Walker:Senior Director Value Expert Engagement &Collaborations, GlaxoSmithKline Robert Nauman:Principal, BioPharma Advisors Ulf Staginnus: Head ofPricing & Health Economics Europe, Novartis and authorof www.healtheconomicsblog.comTable of Contents :
  3. 3. Executive summaryCurrent agreements with payers across Australia, Europe, Canada and the USIntroductionDefining and categorizing schemesDefinitions from the literatureUK definition and categorizationDrivers for schemesFinancial challengesHTA and saying noDealing with uncertaintyCountry trends in schemes and selected case studiesAustraliaBosentan patient registryCanadaClozaril money-back guaranteeDenmarkNo cure, no pay for DiovanFranceRisperdal refundGermanyAclasta refund schemeItalyTarceva discount schemeSutent discount schemeSerbiaAvastin, Erbitux and MabCampath rebate schemesSwedenCrestor and ezetimibe coverage with evidence developmentUKMultiple Sclerosis Risk Sharing SchemeVelcade money back guaranteeLucentis dose capping schemeUSProscar refund schemeZocor refund schemeJanuvia guarantee schemeSanofi and Proctor & Gamble pay for fractures schemePotentials and pitfalls of agreementsFit with pricing and reimbursement environmentsPros and consReality checkConclusionsToo early to sayMaybe necessary, but not sufficient
  4. 4. Exploring uncertainty, not discounting in the futureAcknowledgementsRelated Keywords : Market, Research, Report, Business, Industry, Information, Automotive, Banking, Finance, Food,Beverages, Technology, Biomass, Books, Conference, Company Profiles, CountryFor More details about above & other Reports plz contact :PranaliAarkstore.comContact: Marketing teamMob.No.918149852585Email: enquiry@aarkstore.com , discount@aarkstore.comURL: http://www.aarkstore.comhttp://in.linkedin.com/in/aarkstorehttp://www.facebook.com/aarkstore

×